Cara Therapeutics, Inc. CARA
Set alert
5.32 0.00 0.00%
At close · Apr 15
5.28 Day range 5.52
52-week range unavailable
- YTD
- -71.02%
- 1 year
- -79.19%
- Open
- 4.80
- Prev close
- 5.32
- Mkt cap
- 8.11M
- Vol
- 236.84K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.28
- High
- 5.52
- Forward P/E
- -0.59
- Beta
- 0.68
- Short ratio
- 2.20
- Inst. own
- 28.16%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.29152
- 200-d avg
- 0.46241
- 1y target
- 1.01
Analyst view
Consensus: hold
Hold
Price target (mean) 1.01 -81.0% downside
Now 5.32
- Target (low)
- 1.00
- Target (mean)
- 1.01
- Target (high)
- 1.02
Ratings (0m) 2 0 buy · 2 hold · 0 sell
- Strong buy0
- Buy0
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 2
- 1 month ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 800.00K | -73.4% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 1.20M | -43.8% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 4.80M | -77.1% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 3.60M | -25.0% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 13, 2024 | Canaccord Genuity | Downgrade | Buy | Hold |
| Jun 13, 2024 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Jun 13, 2024 | Needham | Downgrade | Buy | Hold |
| May 23, 2024 | Needham | Reiterated | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 14, 2024 | Needham | Reiterated | Buy | Buy |
| Apr 10, 2024 | Needham | Reiterated | Buy | Buy |
| Mar 6, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Mar 5, 2024 | Needham | Reiterated | Buy | Buy |
| Jan 22, 2024 | Needham | Maintained | Buy | Buy |
| Dec 19, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Dec 18, 2023 | Needham | Maintained | Buy | Buy |
| Nov 14, 2023 | Piper Sandler | Downgrade | Overweight | Neutral |
| Oct 19, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 8, 2023 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 8, 2023 | Needham | Reiterated | Buy | Buy |
| Jun 27, 2023 | Stifel | Reiterated | Buy | Buy |
| Jun 27, 2023 | Jefferies | Reiterated | Buy | Buy |
| May 16, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 16, 2023 | B of A Securities | Maintained | Underperform | Underperform |
| May 16, 2023 | Needham | Reiterated | — | Buy |
| Apr 18, 2023 | Needham | Reiterated | — | Action List Buy |
| Apr 4, 2023 | Needham | Reiterated | — | Buy |
| Mar 8, 2023 | B of A Securities | Downgrade | Neutral | Underperform |
| Mar 7, 2023 | JP Morgan | Maintained | — | Overweight |
| Mar 7, 2023 | Canaccord Genuity | Maintained | — | Buy |
| Mar 7, 2023 | Needham | Maintained | — | Buy |
| Mar 7, 2023 | Piper Sandler | Maintained | — | Overweight |
| Mar 7, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Feb 17, 2023 | Needham | Reiterated | — | Buy |